Risperidone-induced symptomatic hyperprolactinemia in adolescents

Journal of Clinical Psychopharmacology

Volumn 26, Issue 2, 2006, Pages 167-171

  Holzer, Laurent ^a   Eap, Chin B ^b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Hopital de Cery   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CITALOPRAM; CLORAZEPATE; ESCITALOPRAM; FLUVOXAMINE; OLANZAPINE; PROLACTIN; QUETIAPINE; RISPERIDONE; SERTRALINE;

ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; DELAYED PUBERTY; DEPRESSION; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GALACTORRHEA; GYNECOMASTIA; HUMAN; HYPERPROLACTINEMIA; INFERTILITY; LOW DRUG DOSE; MALE; OBSESSIVE COMPULSIVE DISORDER; OSTEOPENIA; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PSYCHOSIS; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; DRUG MONITORING; FEMALE; GALACTORRHEA; GYNECOMASTIA; HUMANS; HYPERPROLACTINEMIA; MALE; PROLACTIN; PSYCHOTIC DISORDERS; RISPERIDONE;

EID: 33646705863     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000203194.58087.9a     Document Type: Article

References (30)

1. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64:2291-2314.
2. Carman J, Peuskens J, Vangeneugden A. Risperidone in the treatment of negative symptoms of schizophrenia: a meta-analysis. Int Clin Psychopharmacol. 1995;10:207-213.
3. Kleinberg DL, Davis JM, De Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999;19:57-61.
4. Kinon BJ, Gilmore JA, Liu H, et al. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28:55-68.
5. Findling RL, Kusumakar V, Daneman D, et al. Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry. 2003;64:1362-1369.
6. Young JL, Zonana HV, Shepler L. Medication noncompliance in schizophrenia: codification and update. J Am Acad Psychiatry Law. 1986;14:105-122.
7. Lacro JP, Dunn LB, Dolder CR, et al. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry. 2002;63:892-909.
8. Dolder CR, Lacro JP, Dunn LB, et al. Antipsychotic medication adherence: is there a difference between typical and atypical agents? Am J Psychiatry. 2002;159:103-108.
9. Alfaro CL, Wudarsky M, Nicolson R, et al. Correlation of antipsychotic and prolactin concentrations in children and adolescents acutely treated with haloperidol, clozapine, or olanzapine. J Child Adolesc Psychopharmacol. 2002;12:83-91.
10. Masi G, Cosenza A, Mucci M. Prolactin levels in young children with pervasive developmental disorders during risperidone treatment. J Child Adolesc Psychopharmacol. 2001;11:389-394.
11. Masi G, Cosenza A, Mucci M, et al. A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone. J Clin Psychiatry. 2003;64:1039-1047.
12. Holtmann M, Gerstner S, Schmidt MH. Risperidone-associated ejaculatory and urinary dysfunction in male adolescents. J Child Adolesc Psychopharmacol. 2003;13:107-109.
13. Glassner Cohen L, Biederman J. Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol. 2001;11:435-440.
14. Frazier JA, Meyer MC, Biederman J, et al. Risperidone treatment for juvenile bipolar disorder: a retrospective chart review. J Am Acad Child Adolesc Psychiatry. 1999;38:960-965.
15. Cannavo S, Venturino M, Curto L, et al. Clinical presentation and outcome of pituitary adenomas in teenagers. Clin Endocrinol. 2003;58:519-527.
16. Duntas LH. Prolactinomas in children and adolescents - consequences in adult life. J Pediatr Endocrinol Metab. 2001;14:1227-1232.
17. Hummer M, Malik P, Gasser RW, Rettenbacher MA, Fleischhacker WW, et al. Osteoporosis in patients with schizophrenia. Am J Psychiatry. 2005;162:162-167.
18. O'Keane V, Meaney AM. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol. 2005;25:26-31.
19. Albrecht A, Morena PG, Baumann P, et al. High dose of depot risperidone in a nonresponder schizophrenic patient. J Clin Psychopharmacol. 2004;24:673-674.
20. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM Expert Group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:1-23.
21. Nakajima M, Terao T, Iwata N, et al. Switching female schizophrenic patients to quetiapine from conventional antipsychotic drugs: effects on hyperprolactinemia. Pharmacopsychiatry. 2005;38:17-19.
22. Iancu I, Ratzoni G, Weitzman A, et al. More fluoxetine experience. J Am Acad Child Adolesc Psychiatry. 1992;31:755-756.
23. Bronzo MR, Stahl SM. Galactorrhea induced by sertraline. Am J Psychiatry. 1993;150:1269-1270.
24. Bonin B, Vandel P, Vandel S. Fluvoxamine and galactorrhea - a case report. Therapie. 1994;49:149-151.
25. Bondolfi G, Rubin C, Bryois C, et al. Galactorrhoea induced by a pharmacodynamic interaction between citalopram, alprazolam and tramadol: a case report. Therapie. 1997;52:76-77.
26. Brun JF. La prolactine dans son contexte neuroendocrinien. J Psychiatr Biol Ther. 1987;25:24-29.
27. Shioiri T, Kita N, Takahashi S. Two cases of alprazolam-induced hyperprolactinemia in patients with panic disorder. Int Clin Psychopharmacol. 1996;11:149-152.
28. Nydick M, Bustos J, Dale JH, et al. Gynecomastia in adolescent boys. JAMA. 1961;178:449-454.
29. Rosen DS. Question from the clinician: adolescent gynecomastia. Pediatr Rev. 2003;24:317-319.
30. Stigler KA, Potenza MN, Posey DJ, et al. Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management. Paediatr Drugs. 2004;6:33-44.